tiprankstipranks
Trending News
More News >
American Shared Hospital Services (AMS)
XASE:AMS
US Market
Advertisement

American Shared Hospital Services (AMS) AI Stock Analysis

Compare
123 Followers

Top Page

AMS

American Shared Hospital Services

(NYSE MKT:AMS)

Rating:70Outperform
Price Target:
$3.00
▲(20.97% Upside)
AMS demonstrates strong revenue growth and strategic international expansion, contributing significantly to its stock score. A stable financial position with low leverage supports its potential. However, challenges such as negative free cash flow and segment-specific revenue declines, coupled with a net loss, temper the overall outlook. Technical indicators suggest a balanced market sentiment, with valuation remaining reasonable.

American Shared Hospital Services (AMS) vs. SPDR S&P 500 ETF (SPY)

American Shared Hospital Services Business Overview & Revenue Model

Company DescriptionAmerican Shared Hospital Services (AMS) is a healthcare company that specializes in providing turnkey technology solutions to hospitals and medical centers. The company focuses primarily on advanced medical equipment for radiosurgery and radiation therapy, offering services that include financing, consulting, and operation management. AMS's core service is leasing and providing Gamma Knife systems, a non-invasive treatment option for brain disorders, to hospitals on a shared or full-time basis.
How the Company Makes MoneyAMS generates revenue through long-term contracts with hospitals and medical centers, where it provides advanced medical equipment like the Gamma Knife on a lease or fee-per-use basis. The company enters into agreements with healthcare facilities to supply and maintain these high-cost technologies, often without the upfront capital expenditure required for purchasing such equipment. Revenue streams include leasing fees, service fees for equipment maintenance, and per-treatment fees. AMS also benefits from strategic partnerships with major equipment manufacturers and healthcare providers, enabling them to offer comprehensive services and equipment upgrades, which contribute significantly to its earnings.

American Shared Hospital Services Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q1-2025)
|
% Change Since: -16.78%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Neutral
While the company experienced significant revenue growth driven by strategic acquisitions and international expansion, it also faced challenges in its Equipment Leasing segment and recorded a net loss. The sentiment is balanced by both positive growth initiatives and negative financial metrics.
Q1-2025 Updates
Positive Updates
Revenue and Growth
Total revenue increased 17% to $6.1 million in Q1 2025 compared to $5.2 million in Q1 2024, driven by the acquisition of the Rhode Island radiation therapy operations and launch of operations in Puebla, Mexico.
Expansion and Strategic Initiatives
The acquisition of a 60% majority interest in three Rhode Island radiation therapy treatment centers and the launch of operations in Puebla, Mexico, represent significant growth steps. Additionally, the upcoming opening of a new center in Guadalajara, Mexico, is expected to further drive growth.
International Business Development
The company is expanding its international presence with the only Gamma Knife centers in Peru and Ecuador, and a new center in Puebla, Mexico. A new center in Guadalajara, Mexico is expected to open by the end of the year.
Negative Updates
Decline in Equipment Leasing Segment
Revenue from the Equipment Leasing segment decreased to $3 million from $4.3 million in Q1 2024. Gamma Knife revenue declined 18% to $2.1 million for Q1 2025 compared to $2.6 million in Q1 2024.
Proton Beam Therapy Revenue Decline
Revenue from proton beam radiation therapy decreased 38% to $1.6 million in Q1 2025 compared to $2.7 million in Q1 2024, due to lower volumes.
Loss in Operating Income and Net Income
Operating income was a loss of $1.3 million compared to a loss of $85,000 in Q1 2024. Net loss attributable to the company was $625,000 or $0.10 per diluted share compared to net income of $119,000 or $0.02 per diluted share for Q1 2024.
Company Guidance
In the first quarter of 2025, American Shared Hospital Services (AMS) reported a 17% increase in revenue year-over-year, reaching $6.1 million. This growth was primarily driven by the Direct Patient Services segment, which saw a remarkable 224% increase in revenue to $3.1 million, largely due to the acquisition of Rhode Island radiation therapy operations and the launch of a facility in Puebla, Mexico. Despite a decline in Equipment Leasing revenue to $3 million, the company is optimistic about future growth, especially with the opening of new international centers. Adjusted EBITDA for the quarter was $949,000, down from $1.75 million in the previous year, primarily due to lower treatment volumes. The company remains confident in its long-term growth strategy, supported by a strong balance sheet with $11.5 million in cash and cash equivalents.

American Shared Hospital Services Financial Statement Overview

Summary
American Shared Hospital Services demonstrates a strong revenue growth trend and a cautiously optimistic profitability outlook. The balance sheet remains stable with low leverage, providing a solid foundation for future growth. Nonetheless, negative free cash flow highlights the need for improved cash management to sustain operations and capital investments.
Income Statement
76
Positive
American Shared Hospital Services shows a positive revenue growth trajectory, with TTM revenue increasing to $29.2M from $28.3M annually. Gross profit margins remain healthy, though there is a notable decrease to 27.1% TTM from 32.4% annually. Net profit margin is positive at 4.9% TTM, reflecting improved profitability from a challenging past. The company shows volatility in EBIT, with a negative margin at -10.3% TTM, indicating operational challenges. EBITDA remains strong, highlighting potential operational efficiency.
Balance Sheet
68
Positive
The balance sheet indicates a stable financial position with a debt-to-equity ratio of 0.15 TTM, which is relatively low and manageable. However, stockholder equity decreased substantially, leading to an inflated equity ratio calculation. Return on equity for TTM stands at 5.9%, showcasing moderate efficiency in generating profits from shareholders' investments. Overall, the company's leverage appears well-managed, though equity fluctuations could pose risks.
Cash Flow
65
Positive
Operating cash flow to net income ratio is strong at 3.1 TTM, which indicates efficient cash generation relative to net income. However, the free cash flow is negative, highlighting potential challenges in covering capital expenditures. The free cash flow to net income ratio is also negative, indicating that the company needs to improve its cash flow management to support growth and investment activities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue28.34M21.32M19.75M17.63M17.84M
Gross Profit9.19M9.34M8.38M6.73M4.47M
EBITDA8.91M6.97M8.44M6.97M-1.14M
Net Income2.19M610.00K1.33M678.00K-7.06M
Balance Sheet
Total Assets60.20M48.16M43.96M45.43M43.65M
Cash, Cash Equivalents and Short-Term Investments11.03M13.69M12.45M8.26M3.96M
Total Debt23.23M15.68M14.31M16.13M14.40M
Total Liabilities30.17M21.88M22.33M21.19M20.00M
Stockholders Equity25.18B22.62M21.63M24.24M19.27M
Cash Flow
Free Cash Flow-7.77M-555.00K6.85M4.59M9.29M
Operating Cash Flow167.00K5.72M7.24M6.27M9.74M
Investing Cash Flow-7.07M-6.27M-388.00K-1.67M-2.39M
Financing Cash Flow4.41M1.91M-2.66M-655.00K-4.81M

American Shared Hospital Services Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.48
Price Trends
50DMA
2.47
Positive
100DMA
2.60
Negative
200DMA
2.86
Negative
Market Momentum
MACD
<0.01
Positive
RSI
45.65
Neutral
STOCH
12.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Negative. The current price of 2.48 is below the 20-day moving average (MA) of 2.55, above the 50-day MA of 2.47, and below the 200-day MA of 2.86, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 12.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMS.

American Shared Hospital Services Risk Analysis

American Shared Hospital Services disclosed 20 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

American Shared Hospital Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$16.00M11.266.16%35.25%175.21%
51
Neutral
$7.39B0.36-62.86%2.37%15.48%-2.68%
51
Neutral
$138.75M12.68-0.21%-26.00%-103.18%
49
Neutral
$40.69M380.0093.38%8.25%1.10%98.13%
49
Neutral
$48.73M-131.17%9.79%-47.01%
48
Neutral
$34.45M-951.52%-0.70%-2.38%
40
Underperform
$22.88M14.03%-29.82%-2.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMS
American Shared Hospital Services
2.48
-0.53
-17.61%
CCM
Concord Medical Services
5.00
-3.00
-37.50%
MODV
ModivCare
2.33
-20.78
-89.92%
CCEL
Cryo-Cell International
4.85
-1.13
-18.90%
DCGO
DocGo
1.39
-2.24
-61.71%
PIII
P3 Health Partners
6.83
-22.70
-76.87%

American Shared Hospital Services Corporate Events

Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
American Shared Hospital Services Appoints New CEO
Positive
Apr 4, 2025

On April 3, 2025, American Shared Hospital Services announced the appointment of Gary Delanois as the new Chief Executive Officer, succeeding Raymond Stachowiak, who will remain as Executive Chairman. The company reported strong financial results for 2024, with a 32.9% increase in revenue driven by strategic expansion and operational strength. The acquisition of radiation therapy centers and new facility openings have been pivotal in this growth. The company is transitioning from a leasing model to a direct provider of radiation therapy services, aiming for sustainable long-term growth through increased patient volumes and operational enhancements.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025